Drug intelligence / Profile preview

tenoxicam + tramadol + morphine + paracetamol + ondansetron

Development stage
Unknown
Lead developer
Ondokuz Mayıs University
Modality
Small Molecules
Administration
Intravenous
01

Overview

This refers to the multimodal analgesia and postoperative nausea and vomiting (PONV) prophylaxis protocol used as the control (Group C) in a prospective observational study conducted by Ondokuz Mayıs University (NCT05752734). The protocol consists of a combination of tenoxicam, tramadol, morphine, paracetamol, and ondansetron. It was evaluated in obese patients undergoing laparoscopic sleeve gastrectomy to compare its efficacy against a group receiving preoperative dexamethasone. The regimen includes intraoperative non-steroidal anti-inflammatory drugs (NSAIDs), opioids, and postoperative analgesics, alongside standard antiemetic prophylaxis. Tenoxicam and paracetamol provide anti-inflammatory and analgesic effects through cyclooxygenase inhibition; tramadol and morphine act as mu-opioid receptor agonists; and ondansetron serves as a 5-HT3 receptor antagonist to prevent postoperative nausea and vomiting.

Other names
group c-Ondokuz Mayıs University-pain (acute postoperative)-nausea and vomiting (postoperative)Group C (NCT05752734)Multimodal analgesia protocol (Ondokuz Mayıs University)
02

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)SERT (Sodium-dependent serotonin transporter)NET (Norepinephrine Transporter)HTR3A (5-hydroxytryptamine receptor 3A)MOR (Mu opioid receptor)PGHS-1 (Prostaglandin G/H Synthase 1)

Beyond the preview

Go deeper on tenoxicam + tramadol + morphine + paracetamol + ondansetron.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on tenoxicam + tramadol + morphine + paracetamol + ondansetron.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call